The industrial hemp issue is taking on a new dimension in Europe. By 2026, the discussion will no longer be limited to cultivation or raw materials, but will also encompass infusions, derivative products, labeling, medical access, and road safety. For both adult consumers and CBD professionals, understanding this evolution is essential to distinguish between what falls under food, medicine, and road safety regulations.
The key point to remember is simple: the new European thresholds being discussed for hemp derivatives are not the same as the thresholds applied in France during roadside saliva tests. This difference changes everything. It also explains why a legally marketed product can still raise questions during a roadside check, especially in a context where semi-synthetic cannabinoids and new “legal” substitutes are proliferating.
More precise European thresholds for hemp derivatives
The EU Council documents from 2026 demonstrate a clear intention: to better regulate hemp-based products by setting more precise limits for certain items. One of the most discussed topics concerns hemp leaves intended for infusions and ready-to-drink infusions, with thresholds expressed in Δ9-THC equivalents.
This development is important because it recognizes that not all hemp derivatives are consumed in the same way. Raw flower, oil, dried infusion, or ready-to-drink beverage do not all involve the same potential exposure. The European Union therefore seems to be moving towards a more nuanced, more technical approach, better suited to actual usage.
Another notable point: the 2026 discussions also mention labeling requirements. For serious players in the sector, this is good news. Clear labeling, laboratory analyses, and harmonized thresholds can strengthen consumer confidence and reduce the grey areas that currently complicate the market.
Why hemp infusions are at the heart of the debate
Hemp infusions occupy a unique place in European regulatory frameworks. Unlike other products, they fall directly under the food category, raising very specific questions about the migration of certain compounds into the final beverage. This is why both leaves intended for infusion and ready-to-drink beverages are subject to particular scrutiny.
For the consumer, this means that a hemp-based product will not necessarily be evaluated solely on its raw composition, but also on its intended use. In practice, regulations are therefore tending to reflect market realities: it's not just what a product contains that matters, but also how it is consumed.
In this context, future European regulations could better structure the market by more clearly separating well-documented and compliant products from those of a less clear nature. For a specialist shop that focuses on lab-tested items, this trend is a step in the right direction: greater clarity also means greater security for the adult consumer seeking legal and traceable products.
France: Medical experimentation remains highly regulated
In France, medical cannabis remains within a specific framework, distinct from that of wellness hemp or everyday CBD products. A TRIS notification from 2025/2026 reiterates that access to medical cannabis products remains strictly limited to five therapeutic indications resulting from French trials.
This point is crucial to avoid confusion. The fact that a hemp- or cannabinoid-based product is available on the market does not mean that it falls under the category of medical cannabis. Similarly, medical cannabis is not the same as wellness products sold in accordance with the regulations applicable to industrial hemp and its derivatives.
The extension of this experimental framework also demonstrates that France is proceeding cautiously. The objective is to maintain targeted, medically supervised access, reserved for specific situations. For the general public, this serves as a reminder that several parallel regulatory frameworks currently exist: food, wellness, medicine, and road safety, each with its own set of rules.
Industrial, medical and wellness hemp: boundaries that need to be clearly understood
The issue of “industrial hemp” can no longer be reduced to agriculture. European and French sources from 2026 show that it now encompasses hemp infusions, medicinal products, new semi-synthetic cannabinoids, and roadside drug testing. This overlap of categories can easily cause confusion for consumers.
To better understand the system, it's necessary to distinguish between three levels. First, there are hemp-derived food and wellness products, which are subject to commercial, analytical, and sometimes food regulations. Second, there are products intended for medicinal purposes, which are accessible within a very limited framework in France. Finally, there are roadside inspection regulations, which follow a public safety logic independent of a product's commercial status.
In short, a product can be compliant for sale, properly labeled, and analyzed, without necessarily offering any specific guarantee regarding saliva testing. This is precisely why we must avoid oversimplification. The new European thresholds mainly concern hemp-based foods and infusions, whereas French roadside checks rely on separate national saliva thresholds.
Roadside drug testing in France: saliva thresholds remain very low
In France, the decree on drug testing, in effect in 2026, maintains very low saliva thresholds for THC. The initial screening threshold is set at 15 ng/ml of saliva, while some analyses or confirmations rely on a threshold of 1 ng/ml of saliva. These levels raise many questions among users of cannabis products.
The main problem is that saliva testing looks for the presence of THC, not for the intent to consume, the context of use, or the effect actually felt at the time of the test. This means that the system does not always clearly distinguish between medical use, residues, recent exposure, or certain situations related to products containing trace amounts of cannabinoids.
For adult consumers, the message must remain very cautious. Even when choosing compliant and tested products, the issue of road safety remains sensitive. Regulations applicable to road traffic are not designed like food marketing regulations; they follow a different, stricter logic, with potentially serious consequences in the event of a positive test.
Why European food thresholds don't solve the issue on the road
It's tempting to believe that European harmonization of hemp-based products will simplify everything. In reality, this is only partially true. The EU's work in 2026 focuses primarily on thresholds in foodstuffs, particularly infusions and certain food derivatives, with labeling requirements and limits adapted to these uses.
Conversely, roadside drug testing in France remains governed by specific national regulations. In other words, a product may comply with European or commercial standards while still posing a risk of difficulty during a saliva test. This is the key area of focus for 2026: European thresholds and roadside drug testing are indeed two separate issues.
This distinction bears repeating, as it now forms the basis of our understanding of the sector. Responsible professionals must therefore clearly inform their clients: legal compliance for sales does not equate to absolute neutrality in road testing. The best approach remains transparency, laboratory analysis, and honest information about the current limitations of the French regulations.
The rise of semi-synthetic cannabinoids further complicates the landscape
The EUDA's 2026 European Drug Report indicates a marked increase in the number of semi-synthetic cannabinoids detected in Europe starting in 2022. By the end of 2025, 40 semi-synthetic cannabinoids had been identified, including substitutes such as HHC acetate and HHC-P. This trend demonstrates how quickly the market is innovating, sometimes even outpacing regulatory controls.
For consumers, these new molecules may give the impression of an easily accessible "legal" space, but the reality is often far more complex. Their status evolves rapidly, quality is not always consistent, and scientific knowledge is sometimes limited. In this context, it is best to favor products that are clearly documented, tested, and accompanied by reliable information.
This surge in semi-synthetic products also has an indirect effect on the image of the entire hemp sector. It is prompting authorities to refine monitoring frameworks and review certain regulatory approaches. For those committed to providing clean, compliant, and traceable CBD, this reinforces the importance of rigorous selection and clear education for adults.
Markets that outpace controls: a real European challenge
EUDA points out that in 2024, at least three THC or semi-synthetic cannabinoid production sites were dismantled in the European Union. This figure illustrates a simple reality: supply chains adapt quickly, product forms change rapidly, and control systems must keep pace with highly responsive markets.
This rapid pace of change explains why European authorities are now seeking to further define thresholds, product categories, and labeling requirements. As the market diversifies, regulations must become clearer. This is particularly true for hemp-based products, which straddle several sectors: agriculture, food, wellness, medicine, and sometimes security.
For savvy shoppers, this situation serves as a reminder of a golden rule: a product's reliability isn't judged solely by its name or packaging. You must examine the analyses, the origin, the exact product category, and the information provided by the seller. In a rapidly changing environment, transparency remains the best guide.
Ultimately, 2026 confirms that industrial hemp and its derivatives are entering a phase of regulatory maturity. Europe is refining its thresholds for certain products such as hemp infusions, France is maintaining highly targeted medical access for five indications, and roadside drug testing continues to rely on particularly low saliva thresholds. Each of these aspects follows a different logic.
For adult consumers in France and Europe, the best approach is to stay informed and selective. Choosing legal, lab-tested, and clearly labeled products is essential, but this doesn't excuse you from exercising maximum caution on the road. In this rapidly evolving sector, clear, honest, and up-to-date information remains the best ally for responsible consumption.
